mRNA Synthesis and Manufacturing Market Seen Reaching $2.96 Billion by 2029

The global mRNA synthesis & manufacturing market is projected to expand from USD 2.23 billion in 2024 to USD 2.96 billion by 2029, registering a compound annual growth rate of 5.8% during the forecast period. The market's upward trajectory is being driven by increasing investments in mRNA-based technologies, particularly in vaccine development and advanced therapeutics. The expanding application scope of mRNA across cell and gene therapy and vaccines continues to unlock new growth opportunities globally.

A key factor accelerating market growth is the heightened focus on mRNA-based vaccines, especially following their successful deployment during the COVID-19 pandemic. This success has catalyzed further research into mRNA applications for infectious diseases, cancer immunotherapies, and rare genetic disorders. Technological advancements in mRNA synthesis, increasing outsourcing activities, and strategic collaborations among biotechnology and pharmaceutical companies are also contributing to market expansion.

The market encompasses consumables and instruments, as well as services such as synthesis, purification, and large-scale manufacturing. By product type, the consumables segment accounted for the largest market share in 2023, attributed to recurring demand for nucleotides, enzymes including RNA polymerase and reverse transcriptase, reagents, buffers, and kits used throughout transcription, purification, and analysis processes. Unlike instruments, which are typically one-time investments, consumables require continuous replenishment, thereby driving consistent revenue generation within this segment.

Based on end users, pharmaceutical and biotechnology companies are expected to register the highest growth rate during the forecast period. This growth is fueled by increased investments in mRNA therapeutics, a growing pipeline of clinical-stage mRNA products, and rising demand for cell and gene therapies. Strategic partnerships and funding initiatives aimed at accelerating mRNA innovation are also strengthening this segment's market position.

Regionally, Asia Pacific is anticipated to witness the fastest growth during the forecast period. The region's rapid expansion is driven by rising healthcare expenditure, increasing prevalence of cancer, and growing investments in biopharmaceutical research and development. China, Japan, and India are emerging as key growth hubs due to favorable regulatory environments, cost advantages, and expanding biotechnology infrastructure.

The market faces challenges including high production costs and stringent regulatory frameworks governing mRNA-based product approvals, which may restrain growth to some extent. The report highlighted leading companies including Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, TriLink BioTechnologies, GenScript, Takara Bio, Lonza, and WuXi Biologics.